In this episode of TechBio Talks, host Najat Khan, PhD, CEO and President of Recursion, talks to Dr. Morgan Cheatham, Partner and Head of Healthcare and Life Sciences at Breyer Capital, about how artificial intelligence and clinical data are converging to transform the measurement of human physiology and disease.
Morgan is a physician, medical geneticist, and investor who has spent nearly a decade backing category-defining companies spanning diagnostics, therapeutics, and care delivery.
They discuss how AI is reshaping the fundamentals of biotech value creation, the vital concept of "modality market fit" for matching therapeutic architectures to patient tolerance, and why the ultimate moat in AI drug discovery is closing the loop between the wet lab, dry lab, and the clinic. Their conversation also covers how recasting medicine as an information science can collapse the barrier between scientific discovery and patient care delivery.
Chapters:
00:00 Introduction
00:57 The Role of Medical Geneticists in Healthcare
03:47 Investing: A Dual Perspective
04:46 Fundamentals of Biotech Value Creation
08:43 Private vs. Public Markets & Discontinuous Tech
12:00 Building the Ultimate Data Moat
13:43 AI as Measurement Tool in Healthcare
18:10 Unlocking Clinical Biobanks
20:42 Precision Therapy & Early Patient Selection
23:48 Defining Modality Market Fit
26:45 Designing for the Patient Experience
29:35 Medicine as an Information Science
31:42 Root Cause Analysis in Medicine and Innovation
33:42 Closing
